2024
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2023
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, Wu A, Du K, Seaward S, Bian S, Aljumaily R, Shivnani A, Knoble J, Crocenzi T, DiPetrillo T, Roof K, Crane C, Goodman K. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology • Biology • Physics 2023, 118: 107-114. PMID: 37598723, PMCID: PMC10843017, DOI: 10.1016/j.ijrobp.2023.08.014.Peer-Reviewed Original ResearchConceptsTarget volumeRadiation therapy quality assuranceRadiation therapyPlanning target volumeClinical treatment volumeGross target volumePretreatment QAContouring atlasTreatment planningResectable pancreatic head adenocarcinomaRT planningIntensity modulated RTQA analysisPancreatic head adenocarcinomaNRG Oncology RTOGPracticing radiation oncologistsReal-time quality assuranceTreatment volumeEffects of RTConcurrent fluoropyrimidineConformal RTAdjuvant chemotherapyRadiation oncologistsQuality assurancePancreas cancerMilestones 2.0: Refining the Competency-Based Assessment of Radiation Oncology Medical Residents
Thomas H, Braunstein S, Golden D, Du K, Weiner A, Bridges K, Vijayakumar S, McLean S, Edgar L, Fields E. Milestones 2.0: Refining the Competency-Based Assessment of Radiation Oncology Medical Residents. International Journal Of Radiation Oncology • Biology • Physics 2023, 115: 12-18. PMID: 36526379, DOI: 10.1016/j.ijrobp.2022.07.1838.Peer-Reviewed Original Research
2022
Milestones 2.0 for Competency-Based Assessment of Radiation Oncology Medical Residents
Thomas H, Braunstein S, Golden D, Du K, Weiner A, Bridges K, Vijayakumar S, McClean S, Edgar L, Fields E. Milestones 2.0 for Competency-Based Assessment of Radiation Oncology Medical Residents. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e498. DOI: 10.1016/j.ijrobp.2022.07.1786.Peer-Reviewed Original ResearchRadiation oncologyCompetency-based assessmentMedical residentsAccreditation Council of Graduate Medical EducationSub-competenciesGraduate Medical EducationImplementation of milestonesPatient-centred careClinical skill developmentCore competenciesModified Delphi methodResident competencyClinical skillsSmall group meetingsPatient careNatural progressionMedical educationAccreditation CouncilRadiation biologyResident developmentACGMEOncologyMedical knowledgeDelphi methodCareDeveloping the Next Iteration of Radiation Oncology Milestones: How to Make Assessment More Useful for Both Residents and Faculty
Thomas H, Braunstein S, Golden D, Du K, Weiner A, Bridges K, Vijayakumar S, McClean S, Edgar L, Fields E. Developing the Next Iteration of Radiation Oncology Milestones: How to Make Assessment More Useful for Both Residents and Faculty. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e5-e6. DOI: 10.1016/j.ijrobp.2022.06.006.Peer-Reviewed Original ResearchRadiation oncologyAccreditation Council of Graduate Medical EducationMedical knowledge competencyClinical radiation oncologistClinical competency committeeGraduate Medical EducationImplementation of milestonesCare delivery pathwaysDevelopment of milestonesMultidisciplinary care teamRadiation oncologistsResidents' clinical competenceAssessment of residentsCore competenciesModified Delphi methodCare teamCompetency-based assessmentResident competencyClinical competenceClinical practiceSmall group meetingsMedical residentsCompetency committeeMedical educationMedical physics
2021
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848.
Tchelebi L, Winter K, Abrams RA, Safran H, Regine WF, McNulty S, Wu AJ, Du KL, Seaward SA, Bian SX, Aljumaily R, Shivnani AT, Moore T, Crocenzi T, DiPetrillo TA, Kuykendal A, Crane CH, Goodman KA. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: S40. PMID: 34700550, DOI: 10.1016/j.ijrobp.2021.07.114.Peer-Reviewed Original ResearchAnalysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, Wu A, Du K, Seaward S, Bian S, Aljumaily R, Shivnani A, Moore T, Crocenzi T, DiPetrillo T, Kuykendal A, Crane C, Goodman K. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s40. DOI: 10.1016/j.ijrobp.2021.07.114.Peer-Reviewed Original ResearchClinical treatment volumePlanning target volumeIntensity-modulated RTTarget volumeRadiation therapy quality assuranceDose-volume histogramsTreatment planning dataGross target volumeTrained radiation oncologistsPretreatment QAVolume histogramsContouring atlasTreatment planningAdjuvant gemcitabine-based chemotherapyResectable pancreatic head adenocarcinomaRT planningIsodose lineQA analysisGemcitabine-based chemotherapyPancreatic head adenocarcinomaNRG Oncology RTOGReal-time quality assurancePre-operative imagingImpact of RTTreatment volumeInterprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
Padilla L, Burmeister JW, Burnett OL, Covington EL, Den RB, Dominello MM, Du KL, Galavis PE, Junell S, Kahn J, Kishore M, Mooney K, Mukhopadhyay ND, Studenski MT, Yechieli RL, Fields EC. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 1058-1065. PMID: 34380009, DOI: 10.1016/j.ijrobp.2021.07.1706.Peer-Reviewed Original ResearchBreaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway.
Modrek AS, Tanese N, Placantonakis DG, Sulman EP, Rivera R, Du KL, Gerber NK, David G, Chesler M, Philips MR, Cangiarella J. Breaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway. Academic Medicine 2021, 96: 518-521. PMID: 33464738, DOI: 10.1097/acm.0000000000003920.Peer-Reviewed Original Research
2020
Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
Padilla L, Burmeister J, Burnett O, Covington E, Den R, Dominello M, Du K, Galavis P, Junell S, Kahn J, Kishore M, Mooney K, Studenski M, Yechieli R, Fields E. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e433. DOI: 10.1016/j.ijrobp.2020.07.2517.Peer-Reviewed Original ResearchA Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Nguy S, Du K. A Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e658-e659. DOI: 10.1016/j.ijrobp.2020.07.1972.Peer-Reviewed Original ResearchEffects of M-CSF Inhibition And Radiotherapy In A Murine Model Of Colorectal Cancer
Nguy S, Diskin B, Adam S, Li E, Liria M, Domogauer J, Taneja S, Teruel J, Wang H, Osterman S, Miller G, Du K. Effects of M-CSF Inhibition And Radiotherapy In A Murine Model Of Colorectal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e543-e544. DOI: 10.1016/j.ijrobp.2020.07.1694.Peer-Reviewed Original ResearchA phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Wu J, Atkinson E, Leichman L, Patel H, Iqbal S, Du K, Bizekis C, Goldberg J, Thomas C, Cohen D, Becker D, Siolas D, Beri N, Oberstein P, Ku G. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2020, 38: 372-372. DOI: 10.1200/jco.2020.38.4_suppl.372.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaClinical CRRadiation therapyPhase I/II studyCarboplatin/paclitaxelEfficacy of nivolumabGrade 2 esophagitisGrade 3/4 AEsGrade 5 toxicityOverall survival benefitPhase II portionSquamous cell carcinomaConcurrent chemoRTManageable toxicityLast dosePrimary endpointII studyUnacceptable toxicityElevated ASTSurvival benefitCell carcinomaChemoRTGrade 3Nivolumab
2019
Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).
Cohen D, Medina B, Du K, Coveler A, Manji G, Oberstein P, Perna S, Miller G. Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC). Journal Of Clinical Oncology 2019, 37: tps4163-tps4163. DOI: 10.1200/jco.2019.37.15_suppl.tps4163.Peer-Reviewed Original ResearchStereotactic body radiotherapyImmune suppressionResection rateUnacceptable toxicityEfficacy of SBRTPhase II multi-institutional studySingle-arm phase II studyAdvanced unresectable pancreatic cancerArm phase II studyHigher R0 resection rateAdaptive immune suppressionImmune suppressive phenotypeM-CSFPD-1 blockadePhase II studyR0 resection rateStandard induction chemotherapyUnresectable pancreatic cancerSurgical resection rateAnti-tumor responseT cell populationsEfficacy of RTPlacement of fiducialsPre-clinical modelsMulti-institutional study
2018
Survival Outcomes and Prognostic Factors for Gastric Cancer in the Adjuvant Setting: An Analysis of the National Cancer Database
Nguy S, Wu P, Lee A, Tam M, Schreiber D, Du K. Survival Outcomes and Prognostic Factors for Gastric Cancer in the Adjuvant Setting: An Analysis of the National Cancer Database. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e49. DOI: 10.1016/j.ijrobp.2018.07.462.Peer-Reviewed Original ResearchFactors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis
Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Julião G, Perez R, Renehan AG. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology 2018, 3: 825-836. PMID: 30318451, DOI: 10.1016/s2468-1253(18)30301-7.Peer-Reviewed Original ResearchConceptsClinical complete responseIndividual participant dataComplete responseLocal regrowthRectal cancerCumulative incidenceParticipant dataNeoadjuvant chemoradiotherapyHazard ratioSustained clinical complete responseProportion of patientsCenter heterogeneityRecent systematic reviewCox frailty modelStage cT1CT2 tumorsMajor surgeryPrimary outcomeTreatment characteristicsChemoradiotherapyLower riskPatientsStudy heterogeneitySystematic reviewNovel management strategiesInitial experience of combination nivolumab and local-regional treatment in patients with advanced hepatocellular carcinoma (HCC).
Gu P, Park J, Zhong J, Guo S, Hickey R, Aaltonen E, Horn J, Du K, Shanbhogue K, Megibow A, Xu R, Kyritsis I, Cohen D, Newman E, Miller G, Welling T. Initial experience of combination nivolumab and local-regional treatment in patients with advanced hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2018, 36: e16149-e16149. DOI: 10.1200/jco.2018.36.15_suppl.e16149.Peer-Reviewed Original ResearchObjective Evaluation of a Didactic Curriculum for the Radiation Oncology Medical Student Clerkship
Golden D, Kauffmann G, McKillip R, Farnan J, Park Y, Schwartz A, Group R, Hirsch A, Warren L, Spektor A, Rudra S, Jimenez R, Colbert L, Gunther J, Das P, Wu A, Du K, Kruser T, Nabavizadeh N, Thomas C, Hara W, McDonald A, Chang E, Braunstein S, Chmura S, Amsbaugh M, Yechieli R, Takita C, Dean M, Asher D, Taunk N, Vargo J, Beriwal S, Ye J, Ballas L, Ballo M, Brower J, Bradley K, Rao Y, Stahl J, Higgins S. Objective Evaluation of a Didactic Curriculum for the Radiation Oncology Medical Student Clerkship. International Journal Of Radiation Oncology • Biology • Physics 2018, 101: 1039-1045. PMID: 29908787, PMCID: PMC6538302, DOI: 10.1016/j.ijrobp.2018.04.052.Peer-Reviewed Original ResearchConceptsRadiation Oncology Education Collaborative Study GroupRadiation oncology clerkshipsRadiation Oncology Education Collaborative Study Group curriculumAcademic medical centerKnowledge assessmentMedical CenterPost-curriculumMultiple academic medical centersAssessment scoresMedical student clerkshipDidactic curriculumLate time pointsCollaborative Study GroupMean assessment scoreStudy groupCurriculum efficacyMedical studentsEducational approachCurriculum exposureCurriculumStudentsStudent clerkshipTime pointsPost-scoresPre-scoresA phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancerDosimetric evaluation of magnetic resonance-generated synthetic CT for radiation treatment of rectal cancer
Wang H, Du K, Qu J, Chandarana H, Das IJ. Dosimetric evaluation of magnetic resonance-generated synthetic CT for radiation treatment of rectal cancer. PLOS ONE 2018, 13: e0190883. PMID: 29304105, PMCID: PMC5755922, DOI: 10.1371/journal.pone.0190883.Peer-Reviewed Original Research